Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
CONCLUSION SB-engineered CAR T cells expand and persist in pediatric and adult B-ALL patients relapsed after HSCT. Antileukemic activity was achieved without severe toxicities.TRIAL REGISTRATION ClinicalTrials.gov NCT03389035.FUNDING This study was supported by grants from the Fondazione AIRC per la Ricerca sul Cancro (AIRC); Cancer Research UK (CRUK); the Fundación Científica de la Asociación Española Contra el Cáncer (FC AECC); Ministero Della Salute; Fondazione Regionale per la Ricerca Biomedica (FRRB).
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Chiara F. Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Giada Matera, Benedetta Cabiati, Chiara Buracchi, Gianmaria Borleri, Grazia Fazio, Silvia Zaninelli, Sarah Tettamanti, Stefania Cesana, Valentina Colom Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biomedical Science | Brain | Cancer | Cancer & Oncology | Grants | Immunotherapy | Leukemia | Neurology | Pediatrics | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants